| Asthma
Alvesco vs Xolair
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Alvesco vs Xolair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXolair has a higher rate of injection site reactions vs Alvesco based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xolair but not Alvesco, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alvesco
Xolair
At A Glance
Oral inhalation
Twice daily
Inhaled corticosteroid
SC injection
Every 2-4 weeks
Anti-IgE antibody
Indications
- Asthma
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- IgE-mediated food allergy
- Chronic Spontaneous Urticaria
Dosing
Asthma 80 mcg twice daily by oral inhalation as starting dose for patients on bronchodilators alone or inhaled corticosteroids, up to 320 mcg twice daily; patients previously on oral corticosteroids start at 320 mcg twice daily (maximum).
Asthma 75 to 375 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
Chronic rhinosinusitis with multiple nasal polyps 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
IgE-mediated food allergy 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
Chronic Spontaneous Urticaria 150 or 300 mg SC every 4 weeks; dosing is not dependent on serum IgE level or body weight.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required
- Known hypersensitivity to ciclesonide or any ingredient of ALVESCO
- Severe hypersensitivity reaction to omalizumab or any ingredient of XOLAIR
Adverse Reactions
Most common (>=3%) Headache, nasopharyngitis, sinusitis, pharyngolaryngeal pain, upper respiratory infection, arthralgia, nasal congestion, pain in extremity, back pain
Serious Oropharyngeal candidiasis, immunosuppression and risk of infections, hypercorticism, adrenal suppression, reduction in bone mineral density, growth effects in pediatric patients, glaucoma, cataracts
Postmarketing Immediate or delayed hypersensitivity reactions including angioedema with swelling of lips, tongue, and pharynx
Most common (>=1%) Arthralgia, pain, injection site reactions, headache, fatigue, dizziness, pruritus, nasopharyngitis, sinusitis, upper respiratory tract infection, dermatitis, earache
Serious Anaphylaxis, malignancies, cardiovascular and cerebrovascular events
Postmarketing Anaphylaxis, eosinophilic conditions, fever with arthralgia and rash (serum sickness-like), severe thrombocytopenia, hair loss
Pharmacology
Ciclesonide is an inhaled corticosteroid prodrug hydrolyzed by esterases to its active metabolite des-ciclesonide, which binds glucocorticoid receptors with 120-fold greater affinity than the parent compound and exerts broad anti-inflammatory activity against mast cells, eosinophils, lymphocytes, macrophages, and neutrophils involved in the asthmatic response.
Omalizumab is a recombinant humanized IgG1 monoclonal antibody that inhibits the binding of IgE to high-affinity IgE receptors (FceRI) on mast cells, basophils, and dendritic cells, resulting in FceRI down-regulation and reduction of IgE-mediated inflammatory responses; in CSU, omalizumab binds to IgE and lowers free IgE levels with down-regulation of IgE receptors, though the exact mechanism by which this results in CSU symptom improvement is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alvesco
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Xolair
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Alvesco
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (3/8) · Qty limit (3/8)
Xolair
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (6/8)
Humana
Alvesco
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (3/3)
Xolair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Alvesco.
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlvescoView full Alvesco profile
XolairView full Xolair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.